Biology Reference
In-Depth Information
101. Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the
XRCC1 gene predicts for response to platinum based treatment in
advanced colorectal cancer. Anticancer Res 2001;
clinical outcome to oxaliplatin-based chemotherapy in metastatic
colorectal cancer. Cancer Chemother Pharmacol 2010;
:493
e
500.
119. Rabik CA, Dolan ME. Molecular mechanisms of resistance and
toxicity associated with platinating agents. Cancer Treatment Rev
2007;
66
:3075
e
9.
102. Wang ZH, Miao XP, Tan W, Zhang XR, Xu BH, Lin DX. [Single
nucleotide polymorphisms in XRCC1 and clinical response to
platin-based chemotherapy in advanced non-small cell
21
:9
e
23.
120. Gillet LC, ScharerOD.Molecularmechanisms ofmammalianglobal
genome nucleotide excision repair. Chem Rev 2006;
33
lung
:865
e
8.
103. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic
polymorphisms are prognostic factors in advanced non-small-cell
lung cancer patients treated with platinum chemotherapy. J Clin
Oncol 2004;
cancer]. Ai Zheng 2004;
23
:253
e
76.
121. Reardon JT, Sancar A. Nucleotide excision repair. Prog Nucleic
Acid Res Mol Biol 2005;
106
:183
e
235.
122. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC.
Enhanced cisplatin cytotoxicity by disturbing the nucleotide
excision repair pathway in ovarian cancer cell lines. Cancer Res
2003;
79
:2594
e
601.
104. Yuan P, Liu L, Wu C, Zhong R, Yu D, Wu J, et al. No association
between XRCC1 polymorphisms and survival in non-small-cell
lung cancer patients treated with platinum-based chemotherapy.
Cancer Biol Ther 2010;
22
:1311
e
6.
123. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP,
Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in
patients with completely resected non-small-cell
63
:854
e
9.
105. Liu L, Yuan P, Wu C, et al. Assessment of XPD Lys751Gln and
XRCC1 T-77C polymorphisms in advanced non-small-cell lung
cancer patients treated with platinum-based chemotherapy. Lung
Cancer; 2010. December 1 [Epub ahead of print].
106. Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and
chemotherapy drug action pathways predict clinical outcomes in
esophageal cancer. J Clin Oncol 2006;
10
lung cancer.
:351
e
60.
124. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in
non-small-cell lung cancer and cisplatin-based adjuvant chemo-
therapy. N Engl J Med 2006;
N Engl J Med 2004;
350
:983
e
91.
125. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene
expressions but not EGFR are predictive of shorter survival in
advanced non-small-cell lung cancer treated with cisplatin and
gemcitabine. Ann Oncol 2006;
355
:3789
e
98.
107. Wei J, Liu B, Zou Z, Qian X, Zhang W, Yu L. ERCC1 mRNA
expression and XRCC1 polymorphism as predictive factors for
overall survival in gastric cancer patients receiving platinum
based chemotherapy. J Clin Oncol 2007;
24
:1818
e
25.
126. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression
correlates with prolonged survival after cisplatin plus gemcita-
bine chemotherapy in non-small cell lung cancer. Clin Cancer Res
2002;
17
(18S):2512.
108. Moreno V, Gemignani F, Landi S, et al. Polymorphisms in genes
of nucleotide and base excision repair: risk and prognosis of
colorectal cancer. Clin Cancer Res 2006;
25
:2286
e
91.
127. Rosell R, Cobo M, Isla D, et al. ERCC1 mRNA-based randomized
phase III trial of docetaxel (doc) doublets with cisplatin (cis) or
gemcitabine (gem)
8
:2101
e
18.
109. Artac M, Bozcuk H, Pehlivan S, et al. The value of XPD and
XRCC1 genotype polymorphisms to predict clinical outcome in
metastatic colorectal carcinoma patients with irinotecan-based
regimens. J Cancer Res Clin Oncol 2010;
12
in stage IV non-small-cell
lung cancer
. Abstract No. 7002.
128. Ryu JS, Hong YC, Han HS, et al. Association between poly-
morphisms of ERCC1 and XPD and survival in non-small-cell
lung cancer patients treated with cisplatin combination chemo-
therapy. Lung Cancer 2004;
(NSCLC) patients (p). J Clin Oncol 2005;
23
:803
e
9.
110. Grimminger PP, Brabender J, Warnecke-Eberz U, et al. XRCC1
gene polymorphism for prediction of response and prognosis in
the multimodality therapy of patients with locally advanced
rectal cancer. J Surg Res 2010;
136
:311
e
6.
129. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-
complementation group 1 polymorphismpredicts overall survival
in advanced non-small cell lung cancer patients treated with
platinum-based chemotherapy. Clin Cancer Res 2004;
44
:e61
e
6.
111. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis
of genomic polymorphisms: prediction of clinical outcome to 5-
FU/oxaliplatin combination chemotherapy in refractory colo-
rectal cancer. Br J Cancer 2004;
164
:4939
e
43.
130. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair
cross-complementation group 1 (ERCC1) single nucleotide
polymorphisms on the prognosis of non-small cell lung cancer
patients. Lung Cancer 2010;
10
:344
e
54.
112. Takanami T, Nakamura J, Kubota Y, Horiuchi S. The Arg280His
polymorphism in X-ray repair cross-complementing gene 1
impairs DNA repair ability. Mutat Res 2005;
91
:135
e
45.
113. Jaremko M, Justenhoven C, Schroth W, et al. Polymorphism of the
DNA repair enzyme XRCC1 is associated with treatment
prediction in anthracycline and cyclophosphamide/methotrexate/
5-fluorouracil-based chemotherapy of patients with primary
invasive
582
:101
e
7.
131. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in
ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer
patients. Clin Cancer Res 2005;
67
:1534
e
8.
132. Li F, Sun X, Sun N, et al. Association between polymorphisms of
ERCC1 and XPD and clinical response to platinum-based
chemotherapy in advanced non-small cell lung cancer. Am J Clin
Oncol 2010;
11
breast
cancer. Pharmacogenet Genomics
2007;
17
:
529
e
38.
114. Kim IS, Kim DC, Kim HG, et al. DNA repair gene XRCC1 poly-
morphisms and haplotypes in diffuse large B-cell lymphoma in
a Korean population. Cancer Genet Cytogenet 2010;
:489
e
94.
133. Wang J, Zhang Q, Zhang H, et al. [Association between poly-
morphisms of ERCC1 and response in patients with advanced
non-small cell lung cancer receiving cisplatin-based chemo-
therapy]. Zhongguo Fei Ai Za Zhi 2010;
33
:31
e
7.
115. Shim HJ, Yun JY, Hwang JE, et al. BRCA1 and XRCC1 poly-
morphisms associated with survival in advanced gastric cancer
treated with taxane and cisplatin. Cancer Sci 2010;
196
:337
e
41.
134. Wei SZ, Zhan P, Shi MQ, et al. Predictive value of ERCC1 and
XPD polymorphism in patients with advanced non-small cell
lung cancer receiving platinum-based chemotherapy: a system-
atic review and meta-analysis. Med Oncol 2011;
13
101
:
1247
e
54.
116. Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in
XRCC1, XRCC3, and CCND1 and survival after treatment for
metastatic breast cancer. J Clin Oncol 2006;
(1):315
e
21.
135. Yin M, Yan J, Voutsina A, et al. No evidence of an association of
ERCC1 and ERCC2 polymorphisms with clinical outcomes of
platinum-based chemotherapies in non-small cell lung cancer:
a meta-analysis. Lung Cancer; 2010::12. November [Epub ahead of
print] 10.1016/j.lungcan.2010.10.011.
28
:5645
e
51.
117. Gao R, Price DK, Dahut WL, Reed E, Figg WD. Genetic poly-
morphisms in XRCC1 associated with radiation therapy in
prostate cancer. Cancer Biol Ther 2010;
24
:13
e
8.
118. Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW. The combination
of ERCC1 and XRCC1 gene polymorphisms better predicts
10
